Introduction {#sec1-1}
============

Viral hepatitis C (HCV) affects approximately 71 million individuals worldwide \[[@ref1]\]. A single-stranded RNA virus of the *Flaviviridae* family, HCV is a major cause of chronic liver disease worldwide \[[@ref2]-[@ref6]\]. As a growing public health threat, HCV is one of the leading causes of disability, morbidity and mortality globally \[[@ref7]\]. Each year, an estimated 700,000 persons die from HCV-related complications, including cirrhosis, hepatocellular carcinoma (HCC) and liver failure \[[@ref8]\]. Unfortunately, many people with HCV only learn about their infection when they develop symptoms from cirrhosis or liver cancer. It is estimated that 21% of acutely infected patients go undiagnosed, while 75-85% become chronically infected \[[@ref9]\]. As a result, there have been renewed international efforts aimed at reducing the global burden of viral hepatitis, including the World Health Organization's (WHO) global health sector strategy on viral hepatitis 2016-2021 \[[@ref10]\].

Based on genomic sequence analysis, there are seven major genotypes (HCV 1-7) including 67 confirmed and 20 provisional subtypes \[[@ref11]\]. Genotype is not only important in predicting the response to therapy but also predicts the risk of disease progression \[[@ref12]\]. Genotype 3 is considered the most poorly understood genotype and has the lowest rate of sustained virologic response (SVR) in the pegylated-interferon era \[[@ref13]\]. Regarded as one of the most difficult subtypes to treat, genotype 3 has a higher rate of disease progression and mortality relative to other genotypes \[[@ref13],[@ref14]\]. According to a meta-analysis, accelerated progression of liver fibrosis associated with genotype 3 had an odds ratio of 1.52 in single biopsy studies compared with other genotypes, suggesting accelerated fibrosis \[[@ref15]\]. Moreover, genotype 3 infection has been associated with a higher incidence of HCC \[[@ref16]\]. Thus, in the last 20 years, more effective treatments have emerged to combat the virulence of genotype 3.

Methodology {#sec1-2}
===========

Studies published between January 2000 and January 2018 were searched in electronic databases according to article titles, abstract contents, and relevance in the field of viral hepatitis C genotype 3. The databases used in this review included PubMed, MEDLINE, Embase, Google Scholar, Scopus, ClinicalTrials.gov and Cochrane Databases. The main search terms used were hepatitis C genotype 3, epidemiology, infection rates, steatosis, fibrosis, HIV coinfection, HCC, insulin resistance (IR), lipid metabolism, treatment, and clinical trials. We also manually searched references to identify additional relevant studies. Articles published in languages other than English were excluded.

Clinical features {#sec1-3}
=================

Epidemiology {#sec2-1}
------------

Genotype 3 represents 20% of all HCV infections worldwide \[[@ref17]\]. It is the second most common genotype in the world, affecting approximately 54.3 million individuals, with approximately 75% of cases occurring in East Asia \[[@ref18]\]. Genotype 3 is responsible for 54-80% of all HCV infections in India, and 79% of all HCV infections in Pakistan, with higher rates reported among drug users \[[@ref17],[@ref19]\]. It is also prevalent in Europe where it accounts for 30% of all HCV infections in Greece, Poland, Denmark, Finland and the UK \[[@ref19]\]. In the US, genotype 3 is the second most common genotype and accounts for 8-13% of all HCV infections \[[@ref20]\]. In Africa, genotype 3 is far less prevalent and makes up approximately 9% of all HCV infections \[[@ref21]\].

Steatosis {#sec2-2}
---------

Steatosis occurs as a result of the excessive accumulation of triglycerides within hepatocytes. A study reviewing liver histopathology found that genotype 3 had the highest prevalence of steatosis when compared to other subtypes \[[@ref22]\]. This is likely due to the cytopathic effect of the genotype, which selectively interferes with the late cholesterol pathway and upregulates the expression of fatty acid synthase; however, steatosis tends to improve with SVR \[[@ref23],[@ref24]\]. Steatosis has also been noted to progress more rapidly into liver fibrosis in patients infected with genotype 3 rather than other genotypes \[[@ref25]\]. However, Chan *et al* reported that while genotype 3 is associated with higher rates of steatosis, current data do not show any enhanced direct viral-mediated hepatic fibrogenesis \[[@ref21]\]. Most studies that reported a potential association with genotype 3 and severity of hepatic fibrosis were limited by small cohorts, variability in patient characteristics, such as insulin resistance (IR), body body mass index or genotype distribution, and discrepancies in methodology, particularly with respect to the grading of steatosis \[[@ref26],[@ref27]\].

A large meta-analysis of 3068 chronic hepatitis C patients from North America, Europe and Australia showed that genotype 3 was associated with steatosis, not fibrosis; multivariate analysis identified steatosis and the level of inflammatory activity on histopathology as independent predictors of disease \[[@ref28]\]. While a direct viral association seems lacking or unclear, some studies have identified a link between higher grades of steatosis and higher rates of fibrosis \[[@ref27]\].

While the precise pathogenic mechanisms of genotype 3-mediated steatosis are still unclear, genotype 3 appears to modulate host lipid metabolism and transportation within hepatocytes via three mechanisms: microsomal triglyceride transfer protein; sterol regulatory element-binding protein 1c; and peroxisome proliferator-associated receptor-α \[[@ref29]\]. Through these pathways, it is thought that intrahepatic fat sequestration or steatosis impairs the response to treatment in patients with fatty liver \[[@ref25]\]. In a large national study of 7248 eligible subjects, the use of statins (n=3334) was significantly associated with better SVR rates after antiviral therapy and lower progression of liver fibrosis and incidence of HCC \[[@ref30]\].

HCV/human immunodeficiency virus (HIV) coinfection {#sec2-3}
--------------------------------------------------

Coinfection with HIV and HCV-3 is relatively common. According to a meta-analysis of over 780 studies, the global prevalence of HCV/HIV coinfection was estimated to be about 6% \[[@ref31]\]. In the US and Western Europe, the prevalence of coinfection is approximately 10-30% \[[@ref32],[@ref33]\]. Coinfection with HCV-3 increases the risk of chronicity while producing a higher viral load and an inability to mount a CD4/CD8 mediated T-cell immune response \[[@ref34]\]. Coinfection has also been associated with an accelerated progression of liver fibrosis and a reduced SVR to interferon-based regimens \[[@ref35]-[@ref37]\]. However, antiretroviral therapy has been shown to ease the progression of HCV-associated liver injury and fibrosis by reducing HIV-related inflammation and immune dysfunction, and limiting infectivity \[[@ref38]-[@ref41]\]. Additionally, HCV treatment in coinfected patients has been associated with a reduction in the frequency of death, HIV progression, liver-related events, and reduced hazards of diabetes mellitus and possibly chronic renal failure \[[@ref42],[@ref43]\]. Since HIV accelerates the natural history of HCV and liver-related complications, it is recommended that all coinfected patients be treated for chronic HCV, except those whose life expectancy is less than a few years and will not be remediated by treatment \[[@ref44]\].

Hyperlipidemia, diabetes mellitus or IR {#sec2-4}
---------------------------------------

Lipid metabolism is intimately involved in the molecular mechanisms of the HCV infectious cycle. HCV replication influences and depends upon cholesterol uptake and efflux through different lipoprotein receptors during its entry into the host's cells \[[@ref45]\]. Very low-density lipoprotein-associated proteins, including apolipoprotein (apo)B, apoE and microsomal triglyceride transfer proteins, have been shown to play a crucial role in the formation of infectious HCV particles, especially pertaining to genotype 3 \[[@ref46]\]. HCV can bind low-density lipoprotein (LDL) receptors and lead to intracellular lipid deposition \[[@ref47]\]. Patients infected with genotype 3 tend to have hypocholesterolemia and hypobetalipoproteinemia, which may account for the direct effect of the virus on lipid metabolism \[[@ref48]\]. It appears that HCV-3 also selectively interferes with the late cholesterol pathway, a phenomenon that appears to disappear with SVR \[[@ref23]\]. Interestingly, high LDL levels tends to predict SVR in patients treated with interferon and ribavirin (RBV) \[[@ref49]\]. Since LDL receptors are involved in HCV entry into hepatocytes, higher LDL levels may decrease the number of LDL receptors on the cell membrane, thus decreasing cellular infectivity \[[@ref49]\].

HCV core protein can induce IR by disturbing the intracellular signaling pathway of insulin \[[@ref50]\]. In genotype 3, the presence of IR may reduce the probability of achieving SVR using interferon and RBV regimens, especially in the setting of steatosis involving more than 33% of the liver \[[@ref51]-[@ref54]\]. However, eradication of HCV appears to improve insulin sensitivity without altering fat deposits, adipokine or glucagon levels, suggesting a direct link between viral activity and IR \[[@ref55]\]. Subjects with normal insulin sensitivity were almost three times more likely to attain SVR than those with IR \[[@ref56]\]. Unfortunately, a prospective cohort study was unable to find an association between IR and SVR rates in genotype 1, 2 or 3 patients \[[@ref57]\]. Additionally, Patel *et al* looked at genotype-specific associations with IR and liver fibrosis. While the study did report an association in genotype 1 patients, no significant association was found in the genotype 3 cohort \[[@ref58]\]. The mechanisms of HCV-mediated IR, SVR, and the genotype-specific associations remain unclear. Fortunately, new direct-acting antiviral (DAA) regimens appear unaffected by IR \[[@ref54]\].

HCC {#sec2-5}
---

The incidence of HCC has been on the rise in the United States and around the world \[[@ref59],[@ref60]\]. Genotype 3 has been associated with significantly higher rates of HCC relative to other genotypes \[[@ref61]\]. McMahon *et al* studied 1080 participants for 11,171 person-years and reported that individuals infected with genotype 3 were at increased risk for HCC and liver-related death \[[@ref62]\]. Another study showed that the risk of HCC, after adjusting for demographic and clinical characteristics, was 80% higher in patients with genotype 3 when compared to genotype 1 \[[@ref63]\]. Likewise, McCombs *et al* showed in a Veteran Affairs (VA) study that the risk for developing HCC was 63% higher with genotype 3 (HR 1.63, 95%CI 1.47-1.79; P\<0.001) compared with genotype 1 \[[@ref14]\]. In addition, Ioannou *et al* (2018) reported that in 62,354 VA patients the treatment of HCV with DAAs reduced the risk of liver cancer by 71% \[[@ref64]\]. The finding emphasizes the need to be vigilant in the diagnosis and early treatment of HCV even with cirrhosis of the liver.

Current DAAs {#sec2-6}
------------

The genetic landscape exhibited by HCV has created a major challenge for developing vaccines and effective pan-genotypic therapies \[[@ref65]\]. Prior to DAAs, pegylated interferon and RBV regimens were the standard of care. However, the main limitation of those regimens was their side effects, dominated by fatigue, influenza-like symptoms, hematologic abnormalities, and neuropsychiatric symptoms \[[@ref66]\]. These side effects have been subverted with DAAs, which treat patients facing major challenges including HCV genetic diversity, viral resistance, the influence of host genetics, advanced liver disease and other comorbidities \[[@ref67]-[@ref69]\].

Major advances in elucidating and characterizing the life cycle of HCV have led to the targeting of key stages of viral replication \[[@ref70],[@ref71]\] ([Fig. 1](#F1){ref-type="fig"}). DAAs target non-structural (NS) viral proteins crucial to viral RNA replication, polyprotein processing, and the assembly of infectious virions \[[@ref72]\]. Currently, DAAs approved by the FDA for the treatment of genotype 3 are (in combination): sofosbuvir, a pangenotypic nucleotide analog inhibitor of HCV NS5B polymerase; daclatasvir, an inhibitor of HCV NS5A metalloprotein; velpatasvir, a next-generation pangenotypic NS5A inhibitor; and glecaprevir and pibrentasvir, a NS3/4A protease inhibitor and NS5A inhibitor, respectively \[[@ref73],[@ref74]\].

![Illustration of stages at which NS5A and NS5B inhibitors take effect](AnnGastroenterol-31-541-g001){#F1}

The ASTRAL-3 trials aimed to evaluate the safety and efficacy of sofosbuvir and velpatasvir in the treatment of patients infected with genotype 3, including treatment-naïve, treatment-experienced patients, and patients with compensated liver cirrhosis \[[@ref75]\]. After 12-week treatment, the sofosbuvir-velpatasvir group achieved an SVR of 95% (95%CI 92-98%), superior to the rate of 80% (95%CI 75-85%) in the sofosbuvir-RBV group (P\<0.001). The most frequently reported side effects were fatigue, headache, nausea, and insomnia.

The combination of glecaprevir and pibrentasvir was tested in the SURVEYOR-2 and ENDURANCE-3 trials \[[@ref76]\]. In SURVEYOR-2 phase II, the combination was tested with or without RBV. The study reported an SVR of 97% for treatment-naïve genotype 3 patients without cirrhosis after 8 weeks of treatment (without RBV). Following 12 weeks of therapy (with or without RBV), treatment-naïve genotype 3 patients showed an SVR of 100%. In SURVEYOR-2 phase III, treatment-experienced patients had either 12 or 16 weeks of glecaprevir/pibrentasvir; in those with cirrhosis treatment-naïve patients had 12 weeks and treatment-experienced patients 16 weeks of therapy \[[@ref77]\]. In treatment-experienced, non-cirrhotic patients, cure rates of 91% and 96% were reported in the 12- and 16-week cohorts, respectively. In the cirrhotic arms, treatment-naïve patients had an SVR of 98% after the 12-week regimen while the treatment-experienced patients had an SVR of 96% after 16 weeks. Studies comparing the efficacy of glecaprevir/pibrentasvir (for 8 weeks) and sofosbuvir/daclatasvir in treatment-naïve non-cirrhotics reported similar safety and SVR profiles \[[@ref78]\]. The study suggested that an 8-week treatment of glecaprevir/pibrentasvir could prove highly efficacious. Adding to the guidelines issued by the European Association for the Study of the Liver (EASL), the American Association for the Study of Liver Diseases and the Infectious Disease Society of America recommend the use of glecaprevir/pibrentasvir for 8 weeks in individuals without cirrhosis ([Table 1](#T1){ref-type="table"}) \[[@ref79]\].

###### 

American Association for the Study of Liver Diseases: genotype 3 treatment recommendations
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In the PROTON trial, a combination of sofosbuvir, interferon and RBV was administered for 12 weeks. It showed an SVR of 96% in treatment-naïve genotype 3 patients, some of whom had cirrhosis \[[@ref80]\]. The BOSON trial, a phase 3 trial, evaluated the same combination, with an SVR of 93% in their treatment-naïve patients (96% in non-cirrhotics and 91% in cirrhotics) \[[@ref78]\]. Interferon-free cohorts receiving sofosbuvir and RBV experienced lower SVRs of 71% and 84% after being treated for 16 and 24 weeks, respectively.

In the FISSION trial, sofosbuvir and RBV for 12 weeks was compared to interferon and RBV for 24 weeks in treatment-naïve patients \[[@ref81]\]. However, the SVRs were only 56% and 63%, respectively. In both groups, cirrhotics had a lower SVR than those without cirrhosis (34% vs. 61% and 30% vs. 71%, respectively). The POSITRON trial was for patients in whom interferon was not an option \[[@ref82]\]. Subjects received sofosbuvir and RBV or placebo for 12 weeks and reported SVRs of 61% and 0% respectively. Cirrhotics had an SVR of 21% which non-cirrhotics achieved an SVR of 68%. Likewise, the VALENCE trial extended the same drug combination of sofosbuvir and RBV to 24 weeks in treatment-naïve patients. However, a much higher SVR was seen in treated patients without cirrhosis (94%) and in cirrhotics (92%) \[[@ref83]\].

The ALLY-3 study included treatment-naïve patients who received a combination of sofosbuvir and daclatasvir over 12 weeks. The combination achieved an SVR of 90% and was well tolerated; the SVR was 58% in cirrhotics and 97% in non-cirrhotics \[[@ref84],[@ref85]\]. ALLY-3 also tested treatment-experienced patients with the same regimen and reported an SVR of 86% overall (69% in cirrhotics and 94% in non-cirrhotics) ([Table 2](#T2){ref-type="table"}).

###### 

Current treatment options with direct acting antivirals
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Velpatasvir (GS-5816) is a potent NS5A inhibitor with activity against genotypes 1-6 \[[@ref86]\]. In the ELECTRON-2 trial, it was evaluated at different doses in combination with different drugs: sofosbuvir with 25 mg of velpatasvir, sofosbuvir with 25 mg of velpatasvir and RBV, sofosbuvir with 100 mg of velpatasvir, and sofosbuvir with 10 mg of velpatasvir and RBV, all in treatment-naïve patients \[[@ref87]\]. The study reported SVRs of 100%, 88%, 96% and 100%, respectively. It was also tested in treatment-experienced patients in the same four arms, where SVRs were 85%, 95%, 100% and 100% in non-cirrhotic patients, and 58%, 85%, 88% and 96% in cirrhotic patients, respectively. The most common adverse effects were fatigue, headache and nausea, all related to RBV.

A recent meta-analysis by Berden *et al* showed that regimens containing sofosbuvir and velpatasvir achieved the highest treatment efficacy with RBV (SVR 99%; 95%CI 98-100%) and without RBV (SVR 97%; 95%CI 95-99%) \[[@ref88]\]. Analysis showed that RBV significantly increased SVR rates in patients with or without liver cirrhosis. The same regimen has also demonstrated high treatment efficacy (SVR 94%) in patients coinfected with HIV-1 and HCV \[[@ref89]\]. As a result, according to the EASL recommendations for the treatment of HCV, genotype 3 mono-infected or HIV-coinfected patients should be treated with sofosbuvir and daclatasvir or with sofosbuvir and velpatasvir (for 12 weeks in treatment-naïve individuals) \[[@ref90]\]. Treatment-experienced individuals are recommended either combinations for an extended duration of 24 weeks or the addition of RBV for 12 weeks.

Today, many of these treatments are very expensive compared to prior regimens of interferon and RBV. The sofosbuvir, ledipasvir and RBV regimen costs approximately \$73,000 per quality-adjusted life year (QALY), whereas the sofosbuvir and daclatasvir combination costs more than \$396,000 per QALY \[[@ref19]\]. However, from a societal perspective, treatment with novel HCV therapies appears to be cost-effective compared to RBV and pegylated interferon-based treatments \[[@ref91],[@ref92]\]. The use of DAAs has led to dramatically higher SVR rates along with fewer side effects. The current recommendations for the treatment of chronic HCV-genotype 3 are summarized in [Table 1](#T1){ref-type="table"}.

Emerging next-generation antivirals {#sec2-7}
-----------------------------------

Future developments consist of next-generation DAAs capable of overcoming resistance barriers and offer a broader spectrum of activity against all genotypes, including glecaprevir, pibrentasvir, voxilaprevir, uprifosbuvir, grazoprevir, ruzasvir, AL-335, simeprevir, and odalasvir \[[@ref93]\]. The C-SWIFT trial combined grazoprevir, elbasvir and sofosbuvir in the treatment of naïve patients with and without cirrhosis \[[@ref94]\]. Non-cirrhotic patients received the therapy for 8 or 12 weeks and achieved SVRs of 93% and 100%, respectively. Cirrhotic patients achieved an SVR of 91% after a 12-week course. Similarly, the C-ISLE study assessed the efficacy and safety of elbasvir and grazoprevir plus sofosbuvir with and without RBV, though in patients with compensated cirrhosis \[[@ref95]\]. Among treatment-naïve participants, SVR at 8-weeks was 91% (21/23) in those treated with RBV. Following treatment for 12-weeks without RBV, SVR was 96% (23/24). Among treatment-experienced participants, with and without RBV, SVR was 94% (17/18) and 100% (17/17) in the 12-week arm, respectively, and 94% (17/18) in the 16-week arm. Five individuals reported significant adverse effects, including pneumonia, chest pain, opiate overdose, cellulitis, and decreased creatinine. Paritaprevir (ABT-450), an NS3/4 inhibitor, is administered with ritonavir (ABT-450/r) \[[@ref96]\]. As a pharmaco-enhancer, ritonavir has no activity against HCV; instead, it inhibits the metabolism of paritaprevir, thereby increasing peak and trough drug exposures and allowing for a once-daily dose of ABT-450 \[[@ref97]\]. The NAVIGATOR trial combined ABT-450/r with ombitasvir (ABT-267), an NS5A inhibitor, for 12 weeks in genotype 3 treatment-naïve non-cirrhotic patients, achieving SVR rates of 50% without RBV and just 9% with RBV \[[@ref98]\]. Though the medication was well tolerated, the low SVRs prompted discontinuation of the trial. Similarly, in patients with or without cirrhosis, the QUARTZ II-III trial combinations of ombitasvir/paritaprevir/ritonavir plus sofosbuvir with or without RBV showed an overall SVR of 98% after 12 weeks \[[@ref98]\]. The study noted that combining DAAs with complementary mechanisms of action and virological targets may be an effective therapeutic strategy.

Other novel inhibitors are being studied, including uprifosbuvir (MK-3682; NS5B inhibitor), ruzasvir (MK8408; NS5A inhibitor), grazoprevir (NS3 inhibitor), and voxilaprevir (NS3/4A inhibitor) \[[@ref99]\]. The C-BREEZE-2 trial looked at the efficacy of ruzasvir and uprifosbuvir in treating genotypes 1 to 6 for 12 weeks \[[@ref100]\]. However, because of the suboptimal genotype 3 SVRs (80% in patients without cirrhosis vs. 68% in patients with cirrhosis), as well as virological relapse, the combination was deemed therapeutically ineffective ([Table 3](#T3){ref-type="table"}).

###### 

Next-generation treatments
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In phase II of C-CREST-2, a triple combination of uprifosbuvir, ruzasvir and grazoprevir was tested \[[@ref101]\]. The overall SVR in genotype 3, treatment-naïve, non-cirrhotic patients ranged from 86-95%, suggesting that the 8-week treatment duration was suboptimal \[[@ref102]\]. In phase III of the C-CREST 2 trial, the same triple combination, with and without RBV, was investigated at 8, 12, and 16 weeks \[[@ref102]\]. The overall SVR for genotype 3 patients was 96%. In the 8-week arm, SVR was 94% and 98%, without and with RBV, respectively. In the cirrhotic subgroup, only 1 patient relapsed out of 74, and this patient was in the 16-week treatment (with RBV) group.

Phase II of the LEPTON trial evaluated a triple combination of sofosbuvir, velpatasvir and GS-9857, a next-generation NS3/4A protease inhibitor \[[@ref100]\]. The treatment was tested in treatment-naïve patients with compensated cirrhosis, interferon/RBV failures with cirrhosis, and DAA failures with and without cirrhosis. The naïve group had a duration of 6 weeks while the experienced group had a duration of 8 weeks. The naïve group had an SVR of 83% while the experienced group had an SVR of 100%, which included four prior DAA non-responders. However, the study was inadequately powered and these results should therefore be interpreted cautiously.

In the POLARIS-3 trial, treatment-naïve and experienced patients with cirrhosis were treated with sofosbuvir and velpatasvir for 12 weeks, or sofosbuvir, velpatasvir, and voxilaprevir for 8 weeks \[[@ref103]\]. The trial enrolled patients who had not previously received treatment with DAAs. Overall, both groups achieved an SVR of 96% after 12-weeks, which included one withdrawn consent and an unrelated death. Treatment-naïve patients with cirrhosis had an SVR of 96% on the triple therapy, while treatment-experienced patients with cirrhosis had an SVR of 97%. About 2% of study participants experienced adverse events.

Finally, MIV-802, an NS5B inhibitor, was tested to assess its antiviral activity against genotype 3 *in vitro* \[[@ref104]\]. Preclinical studies found that MIV-802 had greater antiviral activity against genotype 3 than did sofosbuvir, which supported its consideration for further development \[[@ref105]\]. Overall, next-generation HCV DAAs appear to be clinically effective in treating a wide patient population. SVR rates for next-generation DAAs are either equal to or higher than those for first-generation DAAs. This new class of therapeutics promise to be easy to use, highly efficient, pan-genotypic, once-daily, all-oral, and interferon- and RBV-free \[[@ref93]\].

Future challenges {#sec2-8}
-----------------

HCV drug development in the last decade has overcome many challenges and has addressed gaps in care, such as pan-genotype coverage, adverse side effects, and coverage for HIV coinfected individuals and cirrhotics. Achieving clinical SVR has become less of an issue in genotype 3 infected patients, once considered difficult to treat \[[@ref106]\]. Studies in certain patient populations, such as children, pregnant women and nursing mothers, are lacking and represent an unmet need \[[@ref107]\]. Additionally, while most HCV medications are metabolized by the liver, DAA options for persons with severe chronic kidney disease remain limited or contraindicated \[[@ref108]\]. Furthermore, the sample size from subgroup analysis emerging from the clinical trials of next-generation DAAs must be interpreted cautiously. As a result, larger sample sizes are needed to evaluate the clinical efficacy within special cohorts.

Moreover, given that cost plays a role in the distribution and uptake of treatments, it remains to be seen how cost will affect public health. Our next challenge lies in overcoming cost barriers if we are to truly eradicate HCV genotype 3 \[[@ref109]\]. We must address drug prices to ensure universal access. We must also combine these efforts with harm reduction aimed at reintroducing new and resistant strains of HCV. More importantly, in order to achieve the strategic goal set by the WHO, which aims to eliminate HCV, researchers, healthcare providers, policy makers, affected communities, advocates, pharmaceutical and diagnostics industries, and governments around the world will have to work together \[[@ref110]\]. Falade-Nwulia *et al* noted that reducing reinfection and achieving HCV elimination goals involve coupling HCV treatment with harm reduction and targeted behavioral interventions; reinfection rates should be viewed as an indicator of the uptake of HCV treatment \[[@ref111]\].

Furthermore, although DAAs have been successful in treating HCV, their financial burden does not exclude the possibility of the use and development of a vaccine that may serve a crucial preventative role \[[@ref112]\]. While vaccines are available for preventing hepatitis A and B, the goal of HCV vaccine development is protection from HCV persistence. Several candidate vaccines have progressed to clinical testing after promising results in chimpanzees \[[@ref113]\]. Two vaccination mechanisms are currently being investigated using T-cell mediated immunity and eliciting antibodies \[[@ref114]\]. However, the complex transcriptional profile of hepatitis C continues to be challenge vaccine development.

HCV reinfection should be minimized but not feared as we work towards HCV elimination. Rather, reinfection should be viewed as an indication of the uptake of hepatitis C treatment in populations most likely to sustain ongoing HCV epidemics. HCV reinfections should be minimized by coupling HCV treatment with harm reduction and well-designed targeted behavioral interventions.

Concluding remarks {#sec1-4}
==================

HCV represents a global health threat. Specifically, genotype 3 is known to have a rapid disease progression relative to other genotypes, leading to advanced stages of liver disease far earlier. Through the manipulation of lipid metabolic pathways, steatosis impairs the treatment response. However, even in patients with advanced liver disease, new DAA regimens are slowly turning the tide against genotype 3. A high SVR can be achieved in patients with a spectrum of liver disease, as well as those coinfected with HIV. New DAA regimens are also better tolerated by patients, since they have fewer adverse side-effects. We believe that with this expanded armamentarium, genotype 3 should no longer be considered difficult to treat.
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